Schizophrenia News

People with treatment-resistant schizophrenia experienced improvement with evenamide added to antipsychotics compared with antipsychotics alone, according to results from a 6-week trial.

A biopharmaceutical company has announced positive topline results from its phase 2, randomized, open-label trial of evenamide as an add-on to antipsychotic medication in those with moderate to severe treatment-resistant schizophrenia.

Combining motivational interviews with cognitive behavioral therapy improved negative symptoms of schizophrenia compared with mindfulness sessions, according to findings published in The American Journal of Psychiatry.

A mental health nonprofit has announced 11 companies will make up the inaugural cohort of a program that aims to help startups improve the lives of those with challenges relating to mental health conditions.

A generic pharmaceutical company announced the availability of a schizophrenia and bipolar depression treatment, according to a press release.

SAN DIEGO — Patients with MS were twice as likely to experience psychiatric morbidity, including depression and anxiety, in the prodromal phase compared with healthy controls, according to research presented at ACTRIMS 2023.

For individuals prescribed antipsychotic medication, nonadherence, along with switching and stopping medication, was associated with increases in acute care utilization, according to a study published in BMC Psychiatry.

In children with familial high risk of schizophrenia or bipolar disorder, evidence of motor impairment skills may indicate neurodevelopmental vulnerability for psychosis.

The needs of families are largely unmet when a parent is hospitalized for a mental illness, with the need for a broad range of care models required to address these gaps, according to a study published in BMC Psychiatry.

The percentage of those with schizophrenia who were uninsured decreased after the Affordable Care Act provisions were implemented, researchers reported in JAMA Psychiatry.